Rapamycin is a compound that is used to prevent organ transplant rejection and to coat coronary stents. But according to Dr. Mikhail Blagosklonny, it can serve other purposes. The professor of oncology at Roswell Park Cancer Institute has come up with a hypothesis that rapamycin can be used not only to treat cancer, but to help slow the aging process.
Blagosklonny believes that TOR Signaling, which utilizes rapamycin, can be used in both treatments. The mTOR pathway helps regulate metabolism and physiology. Much of Blagosklonny’s research involves molecular and cellular biology as it relates to protecting healthy cells from damage by cancer, and slowing the aging process and halting age related diseases.
Along with his research work, Mikhail Blagosklonny published numerous papers in peer reviewed journals going back to 2000. Topics he has written about include TOR signaling, selective cancer therapy, and diabetic complications. He is also the editor-in-chief of three different medical related periodicals. They are Aging, Cell Cycle, and Oncotarget. View Mikhail’s profile on Loop
Blagosklonny came to the Roswell Park Cancer Institute in Buffalo, New York in 2009. His main job is to develop various anti-cancer strategies. Some of those strategies involve trying to prevent cancer by slowing the aging process.
Dr. Mikhail Blagosklonny received his PhD from First Pavlov State Medical University of St. Petersburg in Russia. Coming to the United States, he worked as a professor of medicine at New York Medical Center and a senior scientist at Albany’s Ordway Research Institute before going on to Roswell Park. Read more https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en